Albumin Nanoparticles in Cancer Therapeutics: Clinical Status, Challenges, and Future Directions

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Cancer presents a significant global health challenge, with conventional treatments facing limitations like toxicity and drug resistance.
• Nanoparticles, particularly protein-based ones like albumin nanoparticles, show promise for targeted drug delivery in cancer therapy.
• Albumin nanoparticles are favored for their biocompatibility, stability, and ease of modification.

Purpose of the Study:

• To review the potential of albumin-based nanoparticles as anticancer therapeutics.
• To emphasize the advantages, current clinical status, and progress of albumin-based nanoparticles.
• To discuss challenges and future directions for albumin-based nanoparticle drug delivery systems.

Main Methods:

• Literature review focusing on albumin-based nanoparticles in cancer therapy.
• Analysis of clinical approvals and progress of albumin-based nanoparticle formulations.
• Discussion of challenges and future research avenues.

Main Results:

• Abraxane (albumin-bound paclitaxel) approval was a milestone, but further approvals were slow until Fyarro® in 2021.
• Albumin nanoparticles demonstrate significant potential for targeted anticancer drug delivery.
• Several challenges impede the broader clinical approval and application of these nanotherapeutics.

Conclusions:

• Albumin-based nanoparticles represent a promising platform for developing effective and targeted anticancer therapies.
• Overcoming current challenges is crucial for unlocking the full therapeutic potential of albumin nanoparticles.
• Continued research and development are essential for advancing albumin-based nanomedicine in oncology.